Vikrant returns to India after 13 years with an overall distinguished career spanning over 20 years in the healthcare industry, in India and internationally. A graduate of Symbiosis Institute of International Business (SIIB), Pune, Vikrant has worked in many national and international organizations in India, South East Asia and more recently in the GCC (Gulf Cooperation Council) countries wherein he was Vice-President for Novo Nordisk’s GCC business and Corporate Vice President for Saudi Arabia. In an interaction with BioSpectrum, Vikrant Shrotriya talks about his new role and company’s plans for the upcoming year. Edited excerpts;
Congratulations on your new assignment. What new strategies are in store for driving the development of integrated diabetes management solutions in India?
While diabetes treatment remains primarily in the domain of doctors and healthcare providers in India, there are some attempts to bring integrated solutions. We are trying to learn and embrace technology as much as possible and we have taken some steps in various therapy areas globally and locally. We have recently launched a digital solution in Growth disorders and likewise, we will evaluate possibilities in Diabetes and Hemophilia space.
What are the updates on the recent partnership with Abbott? What is in store for the Indian market for this partnership?
While we have a solid partnership for nearly three decades in terms of sales and distribution with Abbott in India, we do not have a formal collaboration when it comes to monitoring and digital integration.
Are you planning any more collaborations and acquisitions in the coming times to enhance your solutions in India?
You can read upto 3 premium stories before you subscribe to Magzter GOLD
Log-in, if you are already a subscriber
Get unlimited access to thousands of curated premium stories and 5,000+ magazines
READ THE ENTIRE ISSUE